Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AMLXthis companyAmylyx Pharmaceuticals, Inc.	$29.48	-7.9×	3.74×	0×	-6.39×	-91.8%	0.0%	0.0%	0.0%	-47.4%	-49.3%	-10.8%	0.02×	1.53×	0×	14.27×	0.0%	3	77.91	2	C
AVXLAnavex Life Sciences Corp.	$1.19	-16.48×	8×	0×	-14.16×	2.3%	0.0%	0.0%	0.0%	-48.9%	-54.2%	-5.1%	0×	2.21×	0×	11.6×	0.0%	1	4.27	2	C
CLNNClene Inc.	$4.41	-2.22×	-3.29×	289.36×	-3.38×	-148.3%	78.5%	-11541.5%	-13086.5%	148.8%	-188.6%	-32.1%	-1.23×	-0.75×	-8.61×	0.83×	0.0%	2	-23.05	2	C
DNLIDenali Therapeutics Inc.	$20.23	-5.56×	2.86×	0×	-5.48×	-94.9%	0.0%	0.0%	0.0%	-50.6%	-52.6%	-14.6%	0.04×	0.34×	0×	9.16×	0.0%	3	2.05	2	C
ELDNEledon Pharmaceuticals, Inc.	$2.83	-2.7×	1.52×	0×	-2.24×	-91.0%	0.0%	0.0%	0.0%	-56.3%	-55.1%	-50.4%	0.01×	0.49×	0×	7.4×	0.0%	1	-4.22	2	C
IONSIonis Pharmaceuticals, Inc.	$28.19	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
Peer median	—	-5.56×	2.86×	0×	-5.48×	-94.9%	0.0%	0.0%	0.0%	-50.6%	-54.2%	-14.6%	0.01×	0.34×	0×	7.4×	0.0%	2	0.89	2	—